Axelspace has been selected for a technology development and demonstration project aimed at expanding opportunities for space demonstration, while SymBio Pharmaceuticals is scheduled to conduct a bulk exercise of its 70th Series of Stock Acquisition Rights. Developments at other companies, including Glad Cube, are also mentioned.
Axelspace has been selected for Phase III of the Space Strategy Fund, reportedly advancing efforts to secure opportunities to develop and demonstrate technologies that reduce the cost and increase the frequency of satellite-based in-orbit demonstrations.
SymBio Pharmaceuticals is conducting a bulk exercise of its 70th Series of Stock Acquisition Rights, with 8.02 million shares expected to be delivered starting on the 2nd.